Loading...
01/10 16:36
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals positive financial performance with significant cost reductions, strong revenue growth in cell engineering, and improved EBITDA. The company has a solid cash position and no bank debt. Despite some uncertainties in the Q&A, the ARPA H contract and government projects provide revenue stability. The company is also exploring new opportunities in SaaS and automation, which could drive future growth. The overall sentiment is positive, with potential for stock price appreciation.
Annual Run Rate Cost Reduction $205,000,000 reduction in annual run rate between Q1 2024 and Q1 2025, exceeding the target of $200,000,000.
Cell Engineering Revenue $38,000,000 in Q1 2025, up 37% year-over-year. Excluding $7,500,000 in noncash revenue, the revenue was $31,000,000, up 10% year-over-year, driven by strong growth with biopharma and government customers.
Biosecurity Revenue $10,000,000 in Q1 2025, with a segment gross margin of 28%.
Cell Engineering R&D Expense Decreased 41% from $82,000,000 in Q1 2024 to $49,000,000 in Q1 2025, driven by restructuring efforts.
Cell Engineering G&A Expense Decreased 53% from $38,000,000 in Q1 2024 to $18,000,000 in Q1 2025, driven by restructuring efforts.
Biosecurity Operating Expenses Decreased 33% year-over-year, driven by restructuring efforts.
Total Company Adjusted EBITDA Negative $47,000,000 in Q1 2025, improved from negative $117,000,000 in Q1 2024, primarily due to improved revenue and reduced operating expenses.
Cash Burn $58,000,000 in Q1 2025, down from $104,000,000 in Q1 2024, a significant decrease due to restructuring.
Cash and Cash Equivalents $517,000,000 on the balance sheet with no bank debt.
Cell Engineering Revenue: Cell engineering revenue was $38,000,000 in Q1 2025, up 37% compared to Q1 2024, driven by strong growth with biopharma and government customers.
New Program Metric: In Q1 2025, Ginkgo supported 123 revenue-generating programs on the cell engineering platform, a 32% increase year-over-year.
Data Points Offering: Ginkgo launched its GDP A1 dataset, showcasing 246 therapeutic antibodies and 10 different developability assays, aimed at generating interest and demand.
Automation Systems: Ginkgo sold a system to Aura Genetics, marking a significant entry into the diagnostics market.
Government Contracts: Ginkgo has 28 government projects across cell engineering and biosecurity, with a contracted backlog of over $180,000,000.
ARPA H Grant: Ginkgo secured a $29,000,000 grant for a program focused on bringing pharmaceutical manufacturing back onshore.
Biosecurity Initiatives: Ginkgo's biosecurity business generated $10,000,000 in revenue in Q1 2025, with a segment gross margin of 28%.
Cost Reduction: Ginkgo achieved a $205,000,000 reduction in annual run rate costs between Q1 2024 and Q1 2025.
Cash Burn: Cash burn in Q1 2025 was $58,000,000, down from $104,000,000 in Q1 2024.
Adjusted EBITDA: Total company adjusted EBITDA in Q1 2025 was negative $47,000,000, improved from negative $117,000,000 in Q1 2024.
Restructuring Efforts: Ginkgo is focused on reaching adjusted EBITDA breakeven by the end of 2026 while maintaining a cash margin of safety.
Market Positioning: Ginkgo is expanding its tools business to offer more direct sales to customer scientists, moving away from solely R&D solutions.
Cash Margin of Safety: The company aims to maintain a cash margin of safety to avoid needing to fundraise unless from a position of strength.
Cost Reduction: Ginkgo Bioworks has achieved a $205 million reduction in annual run rate costs, which is crucial for navigating the tough biotech capital market.
Cash Burn: Cash burn decreased from $104 million in Q1 2024 to $58 million in Q1 2025, indicating improved financial management.
Regulatory Environment: The current regulatory environment poses challenges, with potential impacts from new leadership in the FDA affecting outsourcing and R&D services.
Market Demand: There is a general hesitancy in the biotech sector, leading to reduced outsourcing and increased pressure on service providers.
Government Funding: Concerns exist regarding the stability of government funding for biotechnology, especially with recent budget cuts.
Competitive Pressures: The company faces competitive pressures as the biotech industry experiences a downturn, affecting demand for R&D services.
Economic Factors: The overall economic environment is challenging for biotech, with companies being more protective of their internal teams and less willing to outsource.
Supply Chain Challenges: The company is navigating uncertainties in the supply chain, particularly in the context of reshoring pharmaceutical manufacturing.
Adjusted EBITDA Breakeven Target: Ginkgo aims to reach adjusted EBITDA breakeven by the end of 2026 while maintaining a cash margin of safety.
Cost Reduction: Achieved a $205 million reduction in annual run rate costs between Q1 2024 and Q1 2025, surpassing the initial target of $200 million.
Government Contracts: Ginkgo has 28 government projects with a contracted backlog of over $180 million, indicating strong relationships and opportunities in biosecurity and cell engineering.
Expansion into Tools Business: Ginkgo is expanding its offerings to include tools and automation, allowing for a wider customer base and shorter sales cycles.
New Programs: Ginkgo has launched new programs, including a $29 million ARPA-H funded project aimed at onshoring pharmaceutical manufacturing.
Revenue Guidance: Total revenue is now expected to be between $167 million and $187 million for the year, with cell engineering revenue between $117 million and $137 million, and biosecurity revenue at least $50 million.
Cash Burn: Cash burn in Q1 2025 was $58 million, down from $104 million in Q1 2024, with expectations to further reduce this by Q4 2025.
Future Revenue Expectations: Ginkgo anticipates continued growth in revenue from its tools business, with a conservative estimate of low double-digit million dollar contributions for the year.
Annual Run Rate Cost Reduction: $205,000,000 reduction in annual run rate between Q1 2024 and Q1 2025.
Cash Position: $517,000,000 in cash and cash equivalents on the balance sheet.
Cash Burn: Cash burn in Q1 2025 was $58,000,000, down from $104,000,000 in Q1 2024.
Revenue Guidance: Total revenue expected to be $167,000,000 to $187,000,000 for the year.
ARPA H Contract: $29,000,000 funded program over two years.
Government Projects: 28 government projects with a contracted backlog of over $180,000,000.
Despite strong cash reserves and cost management, the company faces challenges with declining revenues and increased losses in Cell Engineering. Positive aspects include restructuring efforts, optimism about government partnerships, and new product launches. However, the lack of significant revenue growth, increased operating losses, and the necessity to reset commitments with Google Cloud temper the outlook. The Q&A reveals optimism about AI and robotics, but the absence of immediate financial benefits suggests a neutral outlook for the stock price in the short term.
The earnings call presents a mixed picture. While there are positives like improved EBITDA, cost reductions, and strong cash position, there are concerns about macroeconomic uncertainties, execution risks in new markets, and a reduction in biosecurity guidance. The Q&A section reveals potential in automation and RNA solutions but lacks clarity on timelines and geopolitical impacts. Overall, the mixed signals and lack of strong catalysts suggest a neutral stock price movement in the short term.
The earnings call reveals positive financial performance with significant cost reductions, strong revenue growth in cell engineering, and improved EBITDA. The company has a solid cash position and no bank debt. Despite some uncertainties in the Q&A, the ARPA H contract and government projects provide revenue stability. The company is also exploring new opportunities in SaaS and automation, which could drive future growth. The overall sentiment is positive, with potential for stock price appreciation.
The earnings call highlights significant cost reductions, improved cash position, and positive revenue growth in Cell Engineering. Despite challenges in supply chains and government funding, the company's focus on cost management and potential SaaS revenue provides optimism. The Q&A section reveals cautious optimism about government funding and potential SaaS opportunities. The lack of shareholder return plans is a slight negative, but the overall sentiment is positive due to strong financial performance and strategic initiatives.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
